Gulf Coast Consortia (GCC) Research Evaluation and Commercialization Hub

墨西哥湾沿岸联盟 (GCC) 研究评估和商业化中心

• 批准号: 10783414
• 负责人: PETER J DAVIES
• 金额: $ 99.94万
• 依托单位: TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-25 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10783414
• 关键词: Academic Training; Address; Admission activity; Agreement; Area; Award; Biological Sciences; Biomedical Research; Biomedical Technology; Biotechnology; Businesses; Cancer Center; Clinic; Clinical; Clinical Trials; Collaborations; Complex; Development; Ecosystem; Education; Educational Activities; Educational process of instructing; Eligibility Determination; Employment Opportunities; Ensure; Equilibrium; Evaluation Research; Face; Funding; Goals; Growth; Health; Health Professional; Health Sciences; Healthcare; Hospitals; Incubators; Infrastructure; Institution; Intellectual Property; Investments; Joints; Laboratories; Leadership; Legal; Link; Malignant Neoplasms; Marketing; Medical; Medical center; Medicine; Mentors; Mentorship; Methodist Church; Mission; Outcome; Participant; Patients; Personal Satisfaction; Pharmacologic Substance; Process; Records; Research; Research Institute; Research Personnel; Resources; Rice; Services; Small Business Innovation Research Grant; Small Business Technology Transfer Research; Stream; Talents; Technology; Technology Transfer; Texas; Therapeutic; Time; Training; Training Programs; Translating; Trust; Underrepresented Populations; United States National Institutes of Health; Universities; Work; career networking; catalyst; college; commercialization; design; drug development; drug discovery; education resources; experience; gulf coast; improved; innovation; medical schools; member; novel; programs; research facility; success; technology development; timeline

In recent years, the NIH has awarded over $850M annually to the numerous research institutions and hospitals within the Texas Medical Center (TMC; Houston, TX), producing ever-increasing numbers of biomedical discov- eries. Despite this massive investment, only some of these discoveries advance to the clinic, and even fewer are successfully commercialized to improve patient health and well-being. Texas academic entrepreneurs face significant challenges as they seek to commercialize their discoveries, including a lack of training and resources to support early-stage business and technology development. To address these deficiencies, we will establish the Gulf Coast Consortium Research Evaluation and Commercialization Hub (GCC-REACH) as an inte- grated multi-institutional resource wherein nascent academic entrepreneurs work closely with successful life science experts and experienced biotech executives to develop strategic milestone-driven timelines to rapidly validate the commercial value of their discoveries. GCC-REACH will expand the GCC and TMC infrastructure and resources we have designed to support emerging biomedical companies. Academic entrepreneurs will hail from all GCC-affiliated institutions (Baylor College of Medicine, Texas A&M Health Science Center, Houston Methodist Research Institute, MD Anderson Cancer Center, Rice University, Texas Southern University, Univer- sity of Houston, the University of Texas Health Science Center, University of Texas Medical Branch), Houston- area colleges and universities with large historically-underrepresented groups, and other Texas research insti- tutions. The GCC-REACH program will provide managerial oversight, access to vetted resources, and seed funds to assist each entrepreneur in progressing to a clear value-added commercialization inflection point. Significance. Discussions with numerous Texas-based researchers, all GCC-affiliated technology transfer of- fices, successful life science companies, and healthcare investors have indicated widespread support for this initiative, noting that it would help launch new companies and advance biomedical discoveries. Importantly, GCC-REACH will pair entrepreneurs who balance full-time clinical, teaching, and laboratory duties with EIRs and expert teams who will provide mentorship and assistance in completing the market analysis, business plans, and technology development strategies. Value proposition. In combination with substantial multi-institutional support, NIH's $4M investment will enable GCC-REACH to train academic entrepreneurs to successfully commercialize novel discoveries. We expect these entrepreneurs will launch approximately 60 highly-competitive early-stage biomedical companies that will be highly competitive for non-dilutive NIH SBIR/STTR funding and venture investment.

近年来，NIH每年向众多研究机构和医院授予超过8.5亿美元 在德克萨斯州医疗中心（TMC；德克萨斯州休斯顿）内，产生了不断增加的生物医学Discov- 埃里斯。尽管进行了大量投资，但其中只有其中一些发现前往诊所，甚至更少 成功商业化以改善患者的健康和福祉。德克萨斯学术企业家面对 当他们寻求商业化发现的挑战，包括缺乏培训和资源 支持早期业务和技术开发。为了解决这些缺陷，我们将建立 墨西哥湾沿岸联盟研究评估和商业化中心（GCC-REACH） 磨碎的多机构资源，新生的学术企业家与成功的生活紧密合作 科学专家和经验丰富的生物技术高管，以迅速发展战略里程碑式的时间表 验证他们发现的商业价值。 GCC-REACH将扩大GCC和TMC基础设施 我们旨在支持新兴的生物医学公司的资源。学术企业家将冰雹 来自所有海湾合作委员会附属机构（德克萨斯州A＆M健康科学中心，休斯敦贝勒医学院 卫理公会研究所，医学博士安德森癌症中心，莱斯大学，德克萨斯州南部大学，UNIVER- 休斯敦，德克萨斯大学健康科学中心，德克萨斯大学医学分公司），休斯顿 - 具有历史少数群体的大型地区和大学的地区和大学，以及其他得克萨斯州研究机构 提示。 GCC-RECH计划将提供管理监督，访问审查的资源和种子 资金协助每个企业家发展到一个明确增值的商业化拐点。 意义。与众多德克萨斯州的研究人员进行了讨论，所有与海湾合作委员会相关的技术转移 - FICE，成功的生命科学公司和医疗保健投资者已表示对此广泛支持 主动性指出，它将有助于创办新公司并提高生物医学发现。重要的是， 海湾合作委员会（GCC）将与企业家配对，他们的全日制临床，教学和实验室职责与EIR平衡 以及将提供指导和协助的专家团队，以完成市场分析，业务计划， 和技术开发策略。 价值主张。结合大量的多机构支持，NIH的400万美元投资将启用 海湾合作委员会（GCC）培训学术企业家，成功地将新颖的发现商业化。我们期望这些 企业家将成立大约60家高度竞争的早期生物医学公司 对于非债务NIH SBIR/STTR资金和风险投资的竞争力很高。